Repligen/$RGEN
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Repligen
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, and other life science companies. It sells four main product categories: filtration and fluid management is the largest category (about 55% of total revenue), while chromatography, proteins, and process analytics are 21%, 11%, and 13%, respectively. Customers in North America, Europe, and Asia-Pacific contribute about 44%, 37%, and 19% of revenue, respectively.
- Ticker
- $RGEN
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 2,000
- Headquarters
- Waltham, United States
- Website
- www.repligen.com
Repligen Metrics
BasicAdvanced
$9.7B
236.39
$0.73
1.06
-
Price and volume
Market cap
$9.7B
Beta
1.06
52-week high
$198.87
52-week low
$100.99
Average daily volume
1.2M
Financial strength
Current ratio
9.05
Quick ratio
7.298
Long term debt to equity
0.318
Total debt to equity
0.327
Interest coverage (TTM)
2.74%
Profitability
EBITDA (TTM)
144.101
Gross margin (TTM)
53.84%
Net profit margin (TTM)
5.29%
Operating margin (TTM)
8.32%
Effective tax rate (TTM)
20.35%
Revenue per employee (TTM)
$390,000
Management effectiveness
Return on assets (TTM)
1.40%
Return on equity (TTM)
1.99%
Valuation
Price to earnings (TTM)
236.385
Price to revenue (TTM)
12.379
Price to book
4.61
Price to tangible book (TTM)
14.97
Price to free cash flow (TTM)
88.231
Free cash flow yield (TTM)
1.13%
Free cash flow per share (TTM)
1.955
Growth
Revenue change (TTM)
16.49%
Earnings per share change (TTM)
-395.45%
3-year revenue growth (CAGR)
3.31%
10-year revenue growth (CAGR)
23.45%
3-year earnings per share growth (CAGR)
-30.60%
10-year earnings per share growth (CAGR)
11.30%
What the Analysts think about Repligen
Analyst ratings (Buy, Hold, Sell) for Repligen stock.
Analyst projections of the future price of Repligen stock.
Bulls say / Bears say
Q2 organic revenue grew 13%, and Repligen raised its FY26 organic growth outlook to 10.5%–13.5% and adjusted EPS guidance to $2.03–$2.09. Continued order momentum and better visibility into the second half support the higher forecast. (GlobeNewswire)
Growth is broadening beyond filtration: Q2 revenue from proteins rose about 50%, while process analytics grew more than 30%. That strength helps offset softer demand in other product lines. (VectorShift Research)
The planned BioLife acquisition would expand Repligen’s cell-therapy offering with recurring consumables. Repligen expects at least $20 million in first-year synergies and $0.05 of adjusted EPS accretion. (Repligen)
Filtration remains a weak spot: ATF and system demand were muted, and management expects only mid-single-digit filtration growth in 2026. A slower capital-equipment recovery could weigh on overall growth. (Exa)
Q2 GAAP operating income rose only 1% year on year, compared with 55% growth on an adjusted basis. The gap shows that the strong adjusted earnings growth was not yet matched by reported operating profit. (GlobeNewswire)
The BioLife deal brings execution and financing risks: its roughly $1.5 billion value is funded with 64% Repligen shares and 36% cash, and closing remains subject to approvals. Expected synergies may take time to deliver or fall short. (Repligen)
Data summarised monthly by Lightyear AI. Last updated on 1 Oct 2026.
Repligen Financial Performance
Revenues and expenses
Repligen Earnings Performance
Company profitability
Upcoming events
No upcoming events
Repligen News
AllArticlesVideos
BioLife Solutions Shareholders Approve Repligen Merger Agreement
MarketBeat1 week ago
Repligen Q2 Earnings Call Highlights
MarketBeat3 months ago
BioLife Solutions Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of BioLife Solutions, Inc. - BLFS
Business Wire3 months ago
Funds containing Repligen
AllUSDEURGBP
Fund name | Fund size | $RGEN weighting |
|---|---|---|
iShares Healthcare Innovation$HEAL | $1.4B | 0.94% |
iShares Healthcare Innovation€2B78 | €1.2B | 0.94% |
iShares Healthcare Innovation£DRDR | £1B | 0.94% |
SPDR S&P 400 US Mid Cap$SPY4 | $6.3B | 0.32% |
SPDR S&P 400 US Mid Cap£SPX4 | £4.7B | 0.32% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.